Amylyx Pharmaceuticals, Inc. AMLX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$41.28M-25.1% | -$33M+4.0% | -$34.39M+17.0% | -$41.44M-15.4% | -$35.91M+4.4% | ||
| $98K-9.3% | $108K-10.0% | $120K-14.9% | $141K-9.6% | $156K-2.5% | ||
| $6.12M-4.2% | $6.39M-9.8% | $7.08M-3.7% | $7.35M+7.6% | $6.83M+1.4% | ||
| $10K-96.4% | $275K— | —— | —— | $1.87M— | ||
| -$6.67M-452% | -$1.21M— | —— | —— | -$11.88M+55.0% | ||
| -$1.43M+46.1% | -$2.66M— | —— | -$5.64M-542% | -$879K— | ||
| -$53K-112% | $433K— | $0+100% | -$264K— | $0+100% | ||
| -$327K— | $0+100% | -$27K+95.2% | -$559K+6.7% | -$599K-2.2% | ||
| -$36.88M-32.2% | -$27.9M+8.1% | -$30.37M-20.3% | -$25.25M+36.6% | -$39.82M+32.5% | ||
| —— | $86K+258% | $24K+41.2% | $17K+54.5% | $11K-45.0% | ||
| $19.74M-35.2% | $30.45M-48.2% | $58.74M+50.7% | $38.99M-62.4% | $103.65M— | ||
| $36.26M+23.1% | $29.47M— | —— | —— | -$43.66M-167% | ||
| —— | —— | $191.11M— | —— | $65.58M— | ||
| $3.22M— | —— | $191.61M— | —— | $65.66M+59,593% | ||
| -$111K-194% | $118K-21.9% | $151K-75.2% | $608K+209% | $197K+138% | ||
| $2.49M+68.5% | $1.48M-99.1% | $166.63M+10,036% | -$1.68M+90.5% | -$17.62M— | ||
| $609K-42.4% | $1.06M-15.0% | $1.24M-18.4% | $1.52M-10.6% | $1.7M-4.9% | ||
| $4M— | —— | —— | —— | —— | ||
| $98K-9.3% | $108K-10.0% | $120K-14.9% | $141K-9.6% | $156K-2.5% | ||
| —— | $494K0.0% | $494K0.0% | $494K0.0% | $494K+392% | ||
| -$327K— | $0+100% | -$27K+95.2% | -$559K+6.7% | -$599K-2.2% | ||
| $300K+1.7% | $295K-12.2% | $336K-42.5% | $584K+13.4% | $515K+2.2% | ||
| $2K— | —— | —— | -$11K+15.4% | -$13K— | ||
| -$1.43M+46.1% | -$2.66M— | —— | -$5.64M-542% | -$879K— | ||
| -$53K-112% | $433K— | $0+100% | -$264K— | $0+100% | ||
| $4M— | —— | —— | —— | —— | ||
| $7.16M+1,804% | $376K-85.9% | $2.66M+3,593% | $72K-92.6% | $970K+555% | ||
| $3.94M+1,786% | $209K-90.3% | $2.16M+2,001% | $103K-88.4% | $885K+2,229% | ||
| -$327K— | $0+100% | -$27K+95.2% | -$559K+6.7% | -$599K-2.2% | ||
| —— | -$27.99M+7.9% | -$30.39M-20.3% | -$25.27M+36.6% | -$39.84M+32.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Amylyx Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.